Objective:To evaluate the clinical outcomes of radical resection and perioperative management strategies in hepatocellular carcinoma (HCC) patients with major vascular invasion and tumor thrombus.Methods:This is a retrospective case series study. From January 2010 to December 2022,clinicopathological data of 387 HCC patients who underwent liver resection at the Hepatobiliary Center of the First Affiliated Hospital of Nanjing Medical University were retrospectively analyzed. In the cohort,there were 326 males (84.2%) and 61 females (15.8%),with an age ( M(IQR)) of 54(16) years (range: 16 to 82 years). One hundred and nineteen patients (30.7%) had macrovascular invasion without thrombus and 268 patients(69.3%) had macrovascular thrombus. Categorical variables were presented as frequencies (percentages). Survival rates were calculated using life-table analysis,and Kaplan-Meier curves were employed to depict overall survival(OS) and recurrence-free survival (RFS). Independent prognostic factors were identified by univariate and multivariate Cox regression. Results:Among 387 patients,R0 resection was achieved in 359 cases (92.8%),with R1 or R2 resection in 28 cases (7.2%). Excluding in-hospital deaths,the 354 R0-resected patients had a median OS of 19.8 months, with 1-, 3-, and 5-year OS rates were 63.3%, 35.1%, and 22.4%, respectively; median RFS was 5.6 months,and 1-, 3-, and 5-year RFS was 34.0%,18.0%,and 14.4%, respectively. Patients receiving preoperative therapy showed a median OS of 26.0 months,1-, 3-, and 5-year OS rates were 75.5%, 48.4%, and 32.5%, respectively. There was no significant difference in the OS of patients with or without preoperative therapy ( P>0.05). The median OS time of patients who received postoperative adjuvant therapy was 53.0 months, and the 1-, 3-, and 5-year OS rates were 87.9%, 59.2%, and 34.8%, respectively. The median OS time of patients who did not receive postoperative adjuvant therapy was 13.7 months, and 1-, 3-, and 5-year OS rates were 56.7%, 31.7%, and 22.4%, respectively ( P<0.01). The median RFS of patients who received postoperative adjuvant therapy was 11.6 months, and the 1-, 3-, and 5-year RFS rates were 49.6%, 29.8%, and 26.8%, respectively. The median RFS of patients who did not receive postoperative adjuvant therapy was 4.2 months, and the 1-,3-,and 5-year RFS rates were 29.2%, 16.1%, and 12.5%, respectively ( P<0.01). Multivariate analysis identified that maximum tumor diameter,postoperative adjuvant therapy,and treatment after recurrence were the independent predictors of the OS of patients with major vascular invasion and tumor thrombus (all P<0.05),while age,surgical approach,and postoperative adjuvant therapy independently influenced the RFS of patients with major vascular invasion and tumor thrombus(all P<0.05). Conclusions:HCC patients with vascular invasion/thrombus could benefit from surgery-based multimodal therapy after careful evaluation. Postoperative adjuvant therapy significantly reduces recurrence and prolongs patients′ survival.

Objective:To investigate the clinicopathological features, immunophenotype, and gene rearrangement status of hyalinizing clear cell carcinoma (HCCC) of the salivary glands, in order to better understand this rare tumor and improve its precision diagnosis and treatment.Methods:A total of 65 cases of salivary gland HCCC diagnosed at the Peking University School and Hospital of Stomatology, Beijing, China between January 2001 and May 2024 were collected. Clinical features, pathological characteristics, EWSR1 gene rearrangement, and follow-up data were analyzed.Results:There were 33 males and 32 females. The age of the patients ranged from 22 to 85 years, with a median age of 54.0 (40.0, 63.5) years. 93.8% (61/65) of the tumors occurred in the minor salivary glands, most commonly in the palate. Microscopically, the tumors were mainly composed of clear tumor cells. Squamous differentiation was observed in 66.2% (43/65) of the tumors, and mucinous cells in 36.9% (24/65). The tumor stroma showed delicate fibrous septa or hyalinized sheets between tumor nests. Lymph node metastasis occurred in 12.3% (8/65) of the cases, and high-grade transformation was observed in 6.2% (4/65). Tumor cells were all positive for p40 and p63, while SOX10 was positive in 12.3% (8/65) of them. Myoepithelial markers were negative. EWSR1 gene rearrangement was detected in 96.6% of the tumors. Follow-up data showed a 5-year overall survival rate of 93.8%, a local recurrence rate of 9.2%, and a distant metastasis rate of 4.6%.Conclusions:HCCC predominantly arises in minor salivary glands and generally has a favorable prognosis. However, a small proportion of the cases may show high-grade transformation, lymph node metastasis, local recurrence, or distant metastasis. It thus requires long-term and regular follow-up. Accurate diagnosis should be based on a comprehensive assessment of histopathological features, immunophenotype, and gene fusion status.

Objective:To evaluate the clinical outcomes of radical resection and perioperative management strategies in hepatocellular carcinoma (HCC) patients with major vascular invasion and tumor thrombus.Methods:This is a retrospective case series study. From January 2010 to December 2022,clinicopathological data of 387 HCC patients who underwent liver resection at the Hepatobiliary Center of the First Affiliated Hospital of Nanjing Medical University were retrospectively analyzed. In the cohort,there were 326 males (84.2%) and 61 females (15.8%),with an age ( M(IQR)) of 54(16) years (range: 16 to 82 years). One hundred and nineteen patients (30.7%) had macrovascular invasion without thrombus and 268 patients(69.3%) had macrovascular thrombus. Categorical variables were presented as frequencies (percentages). Survival rates were calculated using life-table analysis,and Kaplan-Meier curves were employed to depict overall survival(OS) and recurrence-free survival (RFS). Independent prognostic factors were identified by univariate and multivariate Cox regression. Results:Among 387 patients,R0 resection was achieved in 359 cases (92.8%),with R1 or R2 resection in 28 cases (7.2%). Excluding in-hospital deaths,the 354 R0-resected patients had a median OS of 19.8 months, with 1-, 3-, and 5-year OS rates were 63.3%, 35.1%, and 22.4%, respectively; median RFS was 5.6 months,and 1-, 3-, and 5-year RFS was 34.0%,18.0%,and 14.4%, respectively. Patients receiving preoperative therapy showed a median OS of 26.0 months,1-, 3-, and 5-year OS rates were 75.5%, 48.4%, and 32.5%, respectively. There was no significant difference in the OS of patients with or without preoperative therapy ( P>0.05). The median OS time of patients who received postoperative adjuvant therapy was 53.0 months, and the 1-, 3-, and 5-year OS rates were 87.9%, 59.2%, and 34.8%, respectively. The median OS time of patients who did not receive postoperative adjuvant therapy was 13.7 months, and 1-, 3-, and 5-year OS rates were 56.7%, 31.7%, and 22.4%, respectively ( P<0.01). The median RFS of patients who received postoperative adjuvant therapy was 11.6 months, and the 1-, 3-, and 5-year RFS rates were 49.6%, 29.8%, and 26.8%, respectively. The median RFS of patients who did not receive postoperative adjuvant therapy was 4.2 months, and the 1-,3-,and 5-year RFS rates were 29.2%, 16.1%, and 12.5%, respectively ( P<0.01). Multivariate analysis identified that maximum tumor diameter,postoperative adjuvant therapy,and treatment after recurrence were the independent predictors of the OS of patients with major vascular invasion and tumor thrombus (all P<0.05),while age,surgical approach,and postoperative adjuvant therapy independently influenced the RFS of patients with major vascular invasion and tumor thrombus(all P<0.05). Conclusions:HCC patients with vascular invasion/thrombus could benefit from surgery-based multimodal therapy after careful evaluation. Postoperative adjuvant therapy significantly reduces recurrence and prolongs patients′ survival.

Objective:To investigate the clinicopathological features, immunophenotype, and gene rearrangement status of hyalinizing clear cell carcinoma (HCCC) of the salivary glands, in order to better understand this rare tumor and improve its precision diagnosis and treatment.Methods:A total of 65 cases of salivary gland HCCC diagnosed at the Peking University School and Hospital of Stomatology, Beijing, China between January 2001 and May 2024 were collected. Clinical features, pathological characteristics, EWSR1 gene rearrangement, and follow-up data were analyzed.Results:There were 33 males and 32 females. The age of the patients ranged from 22 to 85 years, with a median age of 54.0 (40.0, 63.5) years. 93.8% (61/65) of the tumors occurred in the minor salivary glands, most commonly in the palate. Microscopically, the tumors were mainly composed of clear tumor cells. Squamous differentiation was observed in 66.2% (43/65) of the tumors, and mucinous cells in 36.9% (24/65). The tumor stroma showed delicate fibrous septa or hyalinized sheets between tumor nests. Lymph node metastasis occurred in 12.3% (8/65) of the cases, and high-grade transformation was observed in 6.2% (4/65). Tumor cells were all positive for p40 and p63, while SOX10 was positive in 12.3% (8/65) of them. Myoepithelial markers were negative. EWSR1 gene rearrangement was detected in 96.6% of the tumors. Follow-up data showed a 5-year overall survival rate of 93.8%, a local recurrence rate of 9.2%, and a distant metastasis rate of 4.6%.Conclusions:HCCC predominantly arises in minor salivary glands and generally has a favorable prognosis. However, a small proportion of the cases may show high-grade transformation, lymph node metastasis, local recurrence, or distant metastasis. It thus requires long-term and regular follow-up. Accurate diagnosis should be based on a comprehensive assessment of histopathological features, immunophenotype, and gene fusion status.

Objective:To systematically review research on the association between vitamin K and type 2 diabetes and diabetes-related biomarkers in humans, and evaluate the role of vitamin K in the prevention of type 2 diabetes.Methods:"Vitamin K", "type 2 diabetes" and related terms were searched in PubMed, EMBASE, China National Knowledge Infrastructure (CNKI) and Wanfang Med Online up to November 2018.Results:A total of 1 Chinese and 12 English articles were included. Among 6 observational studies, 5 of them showed that higher dietary vitamin K intake and plasma vitamin K level were associated with the decrease of the risk of type 2 diabetes. Among 6 clinical intervention studies, 5 of them indicated that the supplementation of vitamin K 1 or K2 could have positive influence on insulin metabolism. One Mendelian randomization study showed higher circulation vitamin K level might reduce the risk of type 2 diabetes. Conclusion:Vitamin K plays an important role in the prevention and control of type 2 diabetes, which may be related to the improvement of insulin metabolism and blood glucose level.

Objective:To systematically review research on the association between vitamin K and type 2 diabetes and diabetes-related biomarkers in humans, and evaluate the role of vitamin K in the prevention of type 2 diabetes.Methods:"Vitamin K", "type 2 diabetes" and related terms were searched in PubMed, EMBASE, China National Knowledge Infrastructure (CNKI) and Wanfang Med Online up to November 2018.Results:A total of 1 Chinese and 12 English articles were included. Among 6 observational studies, 5 of them showed that higher dietary vitamin K intake and plasma vitamin K level were associated with the decrease of the risk of type 2 diabetes. Among 6 clinical intervention studies, 5 of them indicated that the supplementation of vitamin K 1 or K2 could have positive influence on insulin metabolism. One Mendelian randomization study showed higher circulation vitamin K level might reduce the risk of type 2 diabetes. Conclusion:Vitamin K plays an important role in the prevention and control of type 2 diabetes, which may be related to the improvement of insulin metabolism and blood glucose level.

12.08g herbs/kg.The overall effective rate for coronary heart disease was86.8%.CONCLUSION:Danzhisuxin capsule is appropriate in formulation and feasible in preparation technique.The method of quality control is reli?able.No toxic reactions were found and the clinical effect was satisfactory.